Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Central Role For Industry Beckons As Europe Rebuilds After COVID

Generics And Biosimilars Must Become A Central Policy Pillar, Says Rebecca Guntern

Executive Summary

Generic and biosimilar medicines must become central to European healthcare policy as the region looks to rebuild in the wake of the COVID-19 pandemic, Medicines for Europe’s new president, Rebecca Guntern of Sandoz, tells Generics Bulletin in an exclusive interview.

You may also be interested in...



EU Must Stop Offshoring Of Essential Medicines, Say Trade Groups

Current EU policy discourages the domestic manufacturing of essential medicines, say Medicines for Europe and the European Fine Chemicals Group. The associations have called for “immediate, robust and ambitious” policy change to drive manufacturing back home.

European Parliament Urges Increased Role For Generics And Biosimilars

A report adopted by the European Parliament calling for measures to support a “greater market presence for generic and biosimilar medicines” has been welcomed by Medicines for Europe.

Guntern Takes Lead At Medicines For Europe

Sandoz’s Rebecca Guntern has been named as interim president of Medicines for Europe for a three-month term, after Teva’s Christoph Stoller stepped down at the end of his two-year tenure.

Related Content

Topics

UsernamePublicRestriction

Register

GB151351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel